<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01666925</url>
  </required_header>
  <id_info>
    <org_study_id>VAC046</org_study_id>
    <nct_id>NCT01666925</nct_id>
  </id_info>
  <brief_title>Efficacy of Malaria Vaccines in Kenyan Adults</brief_title>
  <official_title>Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malaria transmission is falling in some parts of Africa as bed nets and anti-malarials become&#xD;
      more widely available. However, transmission still persists and it appears that additional&#xD;
      control measures are required. The leading malaria vaccine candidate in development is RTS,S&#xD;
      which has efficacy against clinical malaria measured at 30-50% in the field. This partial&#xD;
      protection might be enhanced by combination with other components. The other vaccination&#xD;
      approach that has produced repeatable efficacy in humans is the use of viral vectors to&#xD;
      induce T cell responses. Previous attempts with this vaccine approach have been effective in&#xD;
      challenge studies in Oxford, but ineffective in the field, probably because of reduced&#xD;
      immunogenicity.&#xD;
&#xD;
      Recently, studies in Oxford, Kenya and the Gambia have shown higher levels of immunogenicity&#xD;
      by using a chimpanzee adenovirus (ChAd63) followed by an attenuated vaccinia virus (modified&#xD;
      vaccinia Ankara) to deliver the pre-erythrocytic antigen, multiple epitope string with&#xD;
      thrombospondin- related adhesion protein (ME-TRAP).&#xD;
&#xD;
      The increase in immunogenicity has lead to sterile protection in 3 out of 14 volunteers and&#xD;
      partial protection in 5 out of 14 volunteers in challenge studies.&#xD;
&#xD;
      The investigators propose a Phase 2b study of 120 healthy adult men in Kenya. The&#xD;
      investigators will assess the efficacy and further evaluate the immunogenicity and safety&#xD;
      profile of the vaccine regimen. The investigators also intend to assess the correlates of&#xD;
      efficacy and natural immunity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Efficacy</measure>
    <time_frame>18 weeks</time_frame>
    <description>The first episode of P.falciparum infection positive by PCR, for P.falciparum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaccine immunogenicity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measures of immunogenicity will include:&#xD;
Ex vivo ELISPOT responses to overlapping pools of ME - TRAP peptides. Cultured ELISPOT responses to overlapping pools of ME - TRAP peptides. ICS by flow cytometry for cell mediated immune responses ELISA for antibodies to malaria antigens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity</measure>
    <time_frame>24 weeks</time_frame>
    <description>All solicited and unsolicited local and systemic vaccine- linked adverse events (AEs) including clinically significant laboratory abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>ChAd63 ME-TRAP and MVA ME-TRAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabies vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x 2.5IU Verorab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation</intervention_name>
    <description>ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu</description>
    <arm_group_label>ChAd63 ME-TRAP and MVA ME-TRAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies vaccine</intervention_name>
    <description>2 x 2.5IU Verorab</description>
    <arm_group_label>Rabies vaccine</arm_group_label>
    <other_name>Verorab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consenting adult males aged 18 - 50 years in good health.&#xD;
&#xD;
          -  Will remain resident in the study area for the study duration.&#xD;
&#xD;
          -  Able and willing (in the Investigator's opinion) to comply with all study requirements&#xD;
&#xD;
          -  Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant medical disease, disorder or finding which may significantly increase&#xD;
             the risk to the volunteer because of participation in the study, affect the ability of&#xD;
             the volunteer to participate in the study or impair interpretation of the study data&#xD;
&#xD;
          -  Hypersensitivity to Verorab, the trial vaccines or the antimalarial used.&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccines, e.g. egg products, kathon, neomycin&#xD;
&#xD;
          -  History of splenectomy.&#xD;
&#xD;
          -  Haemoglobin less than 10.0 g/dl&#xD;
&#xD;
          -  Clinically significant abnormalities of laboratory screening tests (full blood count,&#xD;
             ALT, creatinine levels).&#xD;
&#xD;
          -  Blood transfusion within the month preceding enrolment.&#xD;
&#xD;
          -  History of vaccination with previous experimental malaria vaccines or other vaccines&#xD;
             likely to impact on findings of study (e.g. other MVA or adenovirus vectored vaccines)&#xD;
&#xD;
          -  Administration of any other vaccine or immunoglobulin within 2 weeks before&#xD;
             vaccination.&#xD;
&#xD;
          -  HIV or Hepatitis B surface antigen seropositivity.&#xD;
&#xD;
          -  Current participation in another clinical trial or recent participation within 12&#xD;
             weeks of this study.&#xD;
&#xD;
          -  Any other finding which in the opinion of the investigators would increase the risk of&#xD;
             an adverse outcome from participation in the trial.&#xD;
&#xD;
          -  Likelihood of travel away from the study area&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KEMRI/Wellcome Trust Programme, Centre for Geographic Medicine Research - Coast</name>
      <address>
        <city>Kilifi</city>
        <zip>PO Box 230, 80108</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>August 14, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2012</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

